Binding, Stimulating and Blocking TSH Receptor Antibodies to the Thyrotropin Receptor as Predictors of Relapse of Graves’ Disease after Withdrawal of Antithyroid Treatment

Abstract

TSH-receptor autoantibodies (TRAbs) are a valuable diagnostic tool for comfirming a diagnosis of Graves’ disease (GD). While there is evidence that high TRAb levels are associated with relapse of GD, whether a discrimination of TRAb into stimulating (TSAb) and blocking (TBAb) autoantibodies would benefit the clinician in terms of outcome prediction remains unclear. To address this issue, we have determined TRAb, TSAb and TBAb levels in serum samples of ninety-six euthyroid patients with GD taken four weeks after antithyroid drug withdrawal (ATDT). Forty-seven patients (49 %) underwent relapse of GD within two years. Amongst those, forty-one (87 %) had been positive for TRAb and thirty-five (74 %) for TSAb after treatment. All patients except one were negative for TBAb. The correlation between TRAb and TSAb in those treated GD patients was relatively weak (r = 0.268, p < 0.001). Based on a cut-off limit of 1.5 IU/l, the positive and negative predictive values with respect to prediction of relapse were too low for any clinical relevance (TRAb: 49 % and 54 %; TSAb: 51 % and 55 %). However, when a cut-off level above 10 IU/l was used, the positive and negative predictive values increased to 83 % and 62 %. The additional measurement of TSAb or TBAb in those samples after therapy did not add additional information, even at higher deciscion thresholds. In conclusion, differentiation of TRAb into TSAb and TBAb is of no help in the prediction of relapse of GD in euthyroid patients at the end of ATDT, and only high TRAb levels are associated with relapse.

Key words

Graves’ disease - TSH-receptor antibodies - thyroid stimulating antibodies - thyroid blocking antibodies - relapse

References

• 1 Rapaport B, Chazenbalk G D, Jaume J C, McLachlan S M. The thyrotropin (TSH) receptor: interaction with TSH and autoantibodies.  Endocr Rev. 1998;  19 673-716
• 2 Weetman A P, McGregor A M. Autoimmune thyroid disease: further developments in our understanding.  Endocr Rev. 1994;  15 788-830
• 3 Costagliola S, Morgenthaler N G, Hoermann R, Badenhoop K, Struck J, Freitag D, Poertl S, Weglohner W, Hollidt J M, Quadbeck B, Dumont J E, Schumm-Draeger P M, Bergmann A, Mann K, Vassart G, Usadel K H. Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease.  J Clin Endocrinol Metab. 1999;  84 90-97
• 4 Morgenthaler N G. New assay systems for thyrotropin receptor antibodies.  Curr Opin Endocrinol Diab. 1999;  6 251-260
• 5 Schott M, Feldkamp J, Bathan C, Fritzen R, Scherbaum W A, Seissler J. Detecting TSH-receptor antibodies with the recombinant TBII assay: technical and clinical evaluation.  Horm Metab Res. 2000;  32 429-435
• 6 Maugendre D, Massart C. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.  Clin Endocrinol. 2001;  54 89-96
• 7 Schleusener H, Schwander J, Fischer C, Holle R, Holl G, Badenhoop K, Hensen J, Finke R, Bogner U, Mayr W R. et al . Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease.  Acta Endocrinol (Copenh). 1989;  120 689-701
• 8 Feldt-Rasmussen U, Schleusener H, Carayon P. Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease.  J Clin Endocrinol Metab. 1994;  78 98-102
• 9 Davies T F, Roti E, Braverman L E, DeGroot L J. Thyroid controversy-stimulating antibodies.  J Clin Endocrinol Metab. 1998;  83 3777-3785
• 10 Zimmermann-Belsing T, Nygaard B, Rasmussen A K, Feldt-Rasmussen U. Use of the 2nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves' disease.  Eur J Endocrinol. 2002;  146 173-177
• 11 Rees Smith B, McLachlan S M, Furmaniak J. Autoantibodies to the thyrotropin receptor.  Endocr Rev. 1988;  106 121-132
• 12 Gupta M K. Thyrotropin receptor antibodies in thyroid disease: advances in detection techniques and clinical applications.  Clin Chim Acta. 2000;  293 1-29
• 13 Wallaschowski H, Miehle K, Mayer A, Tuschy U, Hentschel B, Paschke R. Prediction of remission or relapse for Graves’ hyperthyroidism by the combined determination of stimulating, blocking and binding TSH-receptor antibodies after the withdrawal of antithyroid drug treatment.  Horm Metab Res. 2002;  34 383-388
• 14 Hoermann R, Quadbeck B, Roggenbuck U, Szabolcs I, Pfeilschifter J, Meng W, Reschke K, Hackenberg K, Dettmann J, Prehn B, Hirche H, Mann K. Relapse of Graves' disease after successful outcome of antithyroid drug therapy: results of a prospective randomized study on the use of levothyroxine.  Thyroid. 2002;  12 1119-1128
• 15 Saller B, Broda N, Heydarian R, Gorges R, Mann K. Utility of third generation thyrotropin assays in thyroid function testing.  Exp Clin Endocrinol Diabetes. 1998;  106 29-33
• 16 Garry P J, Lashley D W, Owen G M. Automated measurement of urinary iodine.  Clin Chem. 1973;  19 950-953
• 17 Rendl J, Seybold S, Borner W. Urinary iodide determined by paired-ion reversed-phase HPLC with electrochemical detection.  Clin Chem. 1994;  40 908-913
• 18 Morgenthaler N G, Pampel I, Aust G, Seissler J, Scherbaum W A. Application of a bioassay with CHO cells for the routine detection of stimulating and blocking autoantibodies to the TSH-receptor.  Horm Metab Res. 1998;  30 162-168
• 19 Lenzner C, Morgenthaler N G. The effect of thyrotropin-receptor blocking antibodies on stimulating autoantibodies from patients with Graves' disease.  Thyroid. 2003;  13 1153-1161
• 20 Jordan N J, Rinderle C, Ashfield J, Morgenthaler N G, Lazarus J, Ludgate M, Evans C. A luminescent bioassay for thyroid blocking antibodies.  Clin Endocrinol. 2001;  54 355-364
• 21 Glinoer D, de Nayer P, Bex M. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study.  Eur J Endocrinol. 2001;  144 475-483
• 22 Nedrebo B G, Holm P I, Uhlving S, Sorheim J I, Skeie S, Eide G E, Husebye E S, Lien E A, Aanderud S. Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease.  Eur J Endocrinol S. 2002;  147 583-589
• 23 Schott M, Morgenthaler N G, Fritzen R, Feldkamp J, Willenberg H S, Scherbaum W A, Seissler J. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease.  Horm Metab Res. 2004;  36 92-96
• 24 Maugendre D, Massart C. Clinical value of a new TSH binding inhibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves’ disease. Comparison with thyroid stimulating antibody bioassay.  Clin Endocrinol. 2001;  54 89-96
• 25 Mühlberg T, Gilbert J A, Rao P V, McGregor A, Banga P. Dynamics of thyroid-stimulating and -blocking antibodies to the thyrotropin receptor in a murine model of Graves’ disease.  J Clin Endocrinol Metab. 2004;  145 1539-1554
• 26 Sanders J, Jeffreys J, Depraetere H, Richards T, Evans M, Kiddie A, Brereton K, Groenen M, Oda Y, Furmaniak J, Rees Smith B. Thyroid-stimulating monoclonal antibodies.  Thyroid. 2002;  12 1043-1050
• 27 Morgenthaler N G, Minich W B, Willnich M, Bogusch T, Hollidt J M, Weglohner W, Lenzner C, Bergmann A. Affinity purification and diagnostic use of TSH receptor autoantibodies from human serum.  Mol Cell Endocrinol. 2003;  212 73-79
• 28 Massart C, Hody B, Mouchel L, Edan G, Nicol M. Assays for thyrotropin-receptor binding and thyroid-stimulating antibodies in sera from patients with Graves’ disease.  Clin Chem. 1986;  32 1332-1335
• 29 Mukuta T, Tamai H, Oshima A, Morita T, Matsubayashi S, Fukata S, Kuma K. Immunological findings and thyroid function of untreated Graves' disease patients with undetectable TSH-binding inhibitor immunoglobulins.  Clin Endocrinol. 1994;  40 215-219
• 30 Zhu I, Portmann L, Denereaz N, Lemarchand-Beraud T. Simultaneous assay for three types of thyrotropin receptor antibody activities using FRTL-5 cells in patients with autoimmune thyroid disease.  Eur J Endocrinol. 1994;  131 359-368
• 31 Kasagi K, Hikada A, Endo K, Miyamoto S, Takeuchi R, Misaki T, Sakaharah H, Konishi J. Fluctuating thyroid function depending on the balance between stimulating and blocking types of TSH receptor antibodies: a case report.  Thyroid. 1993;  3 315-318
• 32 Takasu N, Yamashiro K, Komiya I, Ochi Y, Sato Y, Nagata A. Remission of Graves’ hyperthyroidism predicted by smooth decrease of thyroid stimulating antibody and thyrotropin binding inhibitor immunoglobulin during antithyroid drug treatment.  Thyroid. 2000;  10 891-896
• 33 Kung A WC, Lau K S, Kohn L D. Characterization of thyroid stimulating blocking antibodies that appeared during transient hypothyroidism after radioiodine therapy.  Thyroid. 2000;  10 909-917
• 34 Kim W B, Chung H K, Lee H K, Kohn L D, Tahara K, Cho B Y. Changes in epitopes for thyroid stimulating antibodies in Graves’ disease sera during treatment of hyperthyroidism: therapeutic implications.  J Clin Endocrinol Metab. 1997;  82 1953-1959
• 35 Brown R S, Bellisario R L, Botero D, Fournier L, Abrams C A, Cowger M L, David R, Fort P, Richman R A. Incidence of transient congenital hypothyroidism due to maternal thyrotropin receptor-blocking antibodies in over one million babies.  J Clin Endocrinol Metab. 1996;  81 1147-1151
• 36 Michelangeli V, Poon C, Taft J, Newnham H, Topliss D, Colman P. The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves’ disease with antithyroid drugs.  Thyroid. 1998;  8 119-124
• 37 Morgenthaler N G, Pampel I, Aust G, Seissler J, Scherbaum W A. Application of a bioassay with CHO cells for the routine detection of stimulating and blocking autoantibodies to the TSH-receptor.  Horm Metab Res. 1998;  30 162-168
• 38 Minich W B, Lenzner C, Bergmann A, Morgenthaler N G. A coated tube assay for the detection of blocking thyrotropin receptor autoantibodies.  J Clin Endocrinol Metab. 2004;  89 352-356